| Discovery of key mechanism underlying idiopathic pulmonary fibrosis
The investigators found that a specific molecular pathway appears responsible for key aspects of the scarring of lung tissue that characterizes IPF, the cause of which is currently unknown. The results will appear in the January issue of Nature Medicine and have received early online release. "Identifying the key role of this pathway in the development of fibrosis gives us an exciting new target for devising treatments," says Andrew Tager, MD, of the MGH Pulmonary and Critical Care Unit, who led the study. "An agent that blocks this pathway is already being developed as a potential cancer treatment, and we're hoping to be able to test it in our animal model of IPF to determine whether it might be a candidate for trials in patients." About 50,000 new cases of IPF are diagnosed in the U.S.
A Second Home for Religious Voters?
Carter was mildly pro-choice, but the party platform he ran on recognized the "religious and ethical nature of the concerns which many Americans have on the subject of abortion." By 1984, something had changed. The Democratic platform declared abortion "a fundamental right." The Democratic nominee, Walter Mondale, began attacking religious conservatives in surefire applause lines. He talked of "radical preachers" and "extremists who control the Republican Party" who could "unleash an orgy of religious intolerance in our land." This was intended to be offensive -- evangelical attendance at orgies is generally low -- and it worked. In the 1984 election, I volunteered for the Reagan campaign. The offenses have continued over the years. "My religion," Democratic Party Chairman Howard Dean once declared, "doesn't inform my public policy" -- a stand that would have been inconceivable to the Rev.
Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated ...
WOODCLIFF LAKE, N.J., Oct. 2 /PRNewswire-FirstCall/ -- Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL) , announced today the launch of its marketing campaign for ENJUVIA(TM) for the treatment of moderate-to-severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy associated with menopause. ENJUVIA(TM) is the first and only oral estrogen approved by FDA for the treatment of these specific symptoms associated with vaginal atrophy. ENJUVIA, a plant-derived oral estrogen therapy is already approved for the treatment of moderate-to- severe vasomotor symptoms (hot flashes and night sweats) associated with menopause. The launch of this new indication comes in conjunction with the North American Menopause Society annual meeting, October 3-6.
|
